Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 25060830 |
CN |
62 | 2 |
Rash vesicular, Herpes zoster, Skin weeping, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 402 | 25061029 |
US |
65 | 1 |
Blood bilirubin increased, Alanine aminotransferase increased, Blood alkaline phosphatase increased, Aspartate aminotransferase increased, Malignant neoplasm progression, |
||||
LENVATINIB, PEMBROLIZUMAB, AMLODIPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, LATANOPROST, LEVOTHYROXINE SODIUM, LORATADINE, LORATADINE ORAL, LORAZEPAM, PANTOPRAZOLE SODIUM, KENALOG, DAPAGLIFLOZIN, ALBUTEROL SULFATE, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, CYANOCOBALAMIN, ROSUVASTATIN, ERGOCALCIFEROL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, LIDOCAINE HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE, BIMATOPROST, TRAMETINIB, DABRAFENIB, |
||||
| 403 | 25055997 |
VN |
||
Malignant neoplasm progression, Pleural effusion, Drug ineffective, |
||||
DURVALUMAB, |
||||
| 404 | 25056067 |
CN |
66 | |
Malignant neoplasm progression, Head discomfort, |
||||
OSIMERTINIB, |
||||
| 405 | 25056110 |
JP |
2 | |
Lung neoplasm malignant, Malignant neoplasm progression, Oedema peripheral, |
||||
CAPMATINIB, |
||||
| 406 | 25055038 |
DE |
2 | |
Polyneuropathy, Neoplasm malignant, Metastases to liver, Metastases to lung, Breast cancer metastatic, Malignant neoplasm progression, Metastases to the mediastinum, Ascites, Pericardial effusion, Pleural effusion, |
||||
LETROZOLE, LETROZOLE TABLETS, FULVESTRANT, PACLITAXEL, CAPECITABINE, IBANDRONATE SODIUM, RIBOCICLIB, RIBOCICLIB, |
||||
| 407 | 25048442 |
IN |
64 | 1 |
Anaemia, Prostatic specific antigen increased, Malignant neoplasm progression, Fatigue, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, DOCETAXEL, DOCETAXEL ANHYDROUS, ABIRATERONE ACETATE, ABIRATERONE, ENZALUTAMIDE, |
||||
| 408 | 25048627 |
JP |
60 | 1 |
Dedifferentiated liposarcoma, Malignant neoplasm progression, Treatment failure, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 409 | 25048872 |
JP |
60 | 2 |
Malignant neoplasm progression, Colitis ulcerative, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 410 | 25049046 |
ZA |
36 | 2 |
Hepatic failure, Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, |
||||
| 411 | 25049067 |
PH |
1 | |
Malignant neoplasm progression, Rash, |
||||
ENZALUTAMIDE, |
||||
| 412 | 25049094 |
PT |
64 | 2 |
Necrosis, Malignant neoplasm progression, Bladder cancer recurrent, Vaginal discharge, Female genital tract fistula, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 413 | 25049135 |
JP |
||
Malignant neoplasm progression, |
||||
CAPIVASERTIB, FULVESTRANT, FULVESTRANT, |
||||
| 414 | 25049316 |
US |
67 | 2 |
Malignant neoplasm progression, |
||||
APIXABAN, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACYCLOVIR, BUPROPION HYDROCHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DULOXETINE HYDROCHLORIDE, DULOXETINE, GLIMEPIRIDE, INSULIN LISPRO, LOSARTAN, MELATONIN, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, PANTOPRAZOLE, PRIMIDONE, ROSUVASTATIN, SOTALOL HYDROCHLORIDE, DULAGLUTIDE, ERGOCALCIFEROL, |
||||
| 415 | 25049341 |
RS |
||
Anaemia, Malignant neoplasm progression, |
||||
OLAPARIB, OLAPARIB, |
||||
| 416 | 25049484 |
JP |
73 | 1 |
Malignant neoplasm progression, Nausea, Anaemia, Neutrophil count decreased, Platelet count decreased, Eastern Cooperative Oncology Group performance status worsened, Rash, Malaise, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED DISODIUM, PEMETREXED, |
||||
| 417 | 25050407 |
IT |
46 | 2 |
Metastases to meninges, Metastatic malignant melanoma, Malignant neoplasm progression, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, TRETINOIN, ARSENIC TRIOXIDE, |
||||
| 418 | 25050475 |
FR |
74 | 2 |
Malignant neoplasm progression, Neuropathy peripheral, Colon operation, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, DOSTARLIMAB, |
||||
| 419 | 25050743 |
CA |
2 | |
Disease recurrence, Synovial cyst, Breast cancer, Malignant neoplasm progression, Drug ineffective, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, |
||||
| 420 | 25050812 |
CA |
61 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Neutrophil count decreased, Eastern Cooperative Oncology Group performance status abnormal, |
||||
LETROZOLE, LETROZOLE TABLETS, RIBOCICLIB, |
||||
| 421 | 25051162 |
JP |
2 | |
Immune-mediated hypothyroidism, Malignant neoplasm progression, Hepatic function abnormal, |
||||
PEMBROLIZUMAB, |
||||
| 422 | 25051182 |
ES |
50 | 1 |
Cervical spinal stenosis, Diverticulum intestinal, Hypertrophy, Abdominal distension, Abdominal distension, Flank pain, Malignant neoplasm progression, Nerve compression, Neuralgia, Mucosal toxicity, Diarrhoea, Mucosal inflammation, Mouth ulceration, Headache, Dizziness, Hypertension, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, LENVATINIB, EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 423 | 25051227 |
NP |
33 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, |
||||
RIBOCICLIB, LETROZOLE, |
||||
| 424 | 25051235 |
ES |
43 | 2 |
Malignant neoplasm progression, Feeling hot, Feeling cold, Night sweats, Acne, Skin discolouration, Skin exfoliation, Swelling, Urine output increased, Decreased immune responsiveness, Inflammation, Weight decreased, Appetite disorder, Dyspepsia, Asthenia, Fatigue, Nausea, Constipation, Influenza like illness, Discomfort, Hyperhidrosis, Abdominal pain, Diarrhoea, Diarrhoea, Dizziness, Pain, Pain, Headache, |
||||
LETROZOLE, LETROZOLE TABLETS, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, GOSERELIN, |
||||
| 425 | 25051238 |
FR |
||
Malignant neoplasm progression, Off label use, |
||||
TREMELIMUMAB, TREMELIMUMAB, DURVALUMAB, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL, |
||||
| 426 | 25051254 |
|||
Myeloproliferative neoplasm, Malignant neoplasm progression, Anaemia, |
||||
RUXOLITINIB, RUXOLITINIB, RUXOLITINIB, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, |
||||
| 427 | 25051304 |
JP |
70 | 2 |
Immune-mediated cholangitis, Hepatitis, Cerebral infarction, Diarrhoea, Malignant neoplasm progression, |
||||
NIVOLUMAB, APREPITANT, FOSAPREPITANT DIMEGLUMINE, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, PALONOSETRON HYDROCHLORIDE, VONOPRAZAN FUMARATE, |
||||
| 428 | 25052194 |
US |
67 | 1 |
Malignant neoplasm progression, Rash, |
||||
AXITINIB, |
||||
| 429 | 25052222 |
JP |
8 | 1 |
Malignant neoplasm progression, Hypothyroidism, General physical health deterioration, |
||||
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, |
||||
| 430 | 25052245 |
JP |
79 | 1 |
Malignant neoplasm progression, |
||||
LENVATINIB, ATEZOLIZUMAB, BEVACIZUMAB, DURVALUMAB, TREMELIMUMAB, PEMBROLIZUMAB, |
||||
| 431 | 25052528 |
SE |
82 | 2 |
Escherichia sepsis, Inflammation, Bone marrow disorder, Pleural effusion, Hepatic lesion, Malignant neoplasm progression, Haemoglobin decreased, Constipation, |
||||
PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, APIXABAN, METHADONE HYDROCHLORIDE, METHADONE, |
||||
| 432 | 25052540 |
RU |
49 | 2 |
Hydronephrosis, Fistula discharge, Stoma site complication, Malignant neoplasm progression, Asthenia, Diarrhoea, Off label use, |
||||
CETUXIMAB, CETUXIMAB, CETUXIMAB, |
||||
| 433 | 25052671 |
CA |
2 | |
Malignant neoplasm progression, |
||||
FULVESTRANT, |
||||
| 434 | 25057898 |
84 | 2 | |
Malignant neoplasm progression, |
||||
BENRALIZUMAB, |
||||
| 435 | 25043463 |
JP |
||
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 436 | 25043489 |
US |
||
Malignant neoplasm progression, Anaemia, |
||||
OLAPARIB, OLAPARIB, |
||||
| 437 | 25044551 |
RU |
53 | 2 |
Hemiparesis, Epilepsy, Malignant neoplasm progression, Neuropathy peripheral, |
||||
CAPECITABINE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, BEVACIZUMAB, BEVACIZUMAB, CISPLATIN, |
||||
| 438 | 25044735 |
US |
69 | 2 |
COVID-19, Blood sodium abnormal, Malignant neoplasm progression, Diarrhoea, Oral mucosal eruption, Diarrhoea, Epistaxis, Taste disorder, Nasopharyngitis, |
||||
AFATINIB, AFATINIB, AFATINIB, |
||||
| 439 | 25044741 |
JP |
8 | 2 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 440 | 25045399 |
MX |
67 | 2 |
Lung disorder, Condition aggravated, Agitation, Thyroid disorder, Swelling, Pulmonary oedema, Chronic myeloid leukaemia, Malignant neoplasm progression, Dyspnoea, Myocardial infarction, Pneumonitis, Cardiac disorder, |
||||
NILOTINIB, |
||||
| 441 | 25045489 |
JP |
74 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 442 | 25045698 |
PL |
75 | 2 |
Malignant neoplasm progression, Demyelination, Neurodegenerative disorder, Prescribed underdose, |
||||
CARBOPLATIN, NIVOLUMAB, IPILIMUMAB, PACLITAXEL, |
||||
| 443 | 25045747 |
JP |
58 | |
Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, |
||||
| 444 | 25046122 |
JP |
8 | 1 |
Malignant neoplasm progression, Tumour lysis syndrome, Pyrexia, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, CISPLATIN, CISPLATIN, |
||||
| 445 | 25046275 |
JP |
||
Malignant neoplasm progression, Fall, Spinal column injury, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 446 | 25046396 |
US |
64 | 2 |
Pancreatic carcinoma, Malignant neoplasm progression, Decreased appetite, Fatigue, Abdominal pain, Diarrhoea, Platelet count decreased, Blister, Insomnia, Flatulence, Macule, Heart rate increased, Blood pressure decreased, Back pain, Pain, Off label use, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, CABOZANTINIB, CABOZANTINIB, ZOLPIDEM TARTRATE, CEFUROXIME, FENTANYL, GABAPENTIN, METOPROLOL TARTRATE, METOPROLOL, MODAFINIL, MUPIROCIN, MUPIROCIN CALCIUM, NAPROXEN, NAPROXEN SODIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OXYCODONE, BISMUTH SUBSALICYLATE, OMEPRAZOLE MAGNESIUM, QUETIAPINE, SERTRALINE, ALPRAZOLAM, PROMETHAZINE, TOPIRAMATE, TOPIRAMATE SPINKLE, |
||||
| 447 | 25046485 |
PL |
67 | 2 |
Dehydration, Acute kidney injury, COVID-19, Aspartate aminotransferase increased, Malignant neoplasm progression, Blood creatinine increased, Diarrhoea, Alanine aminotransferase increased, Vomiting, Nausea, |
||||
FULVESTRANT, ABEMACICLIB, ABEMACICLIB, ZOLEDRONIC ACID, DENOSUMAB, |
||||
| 448 | 25046488 |
JP |
64 | 2 |
Intestinal perforation, Malignant neoplasm progression, Female genital tract fistula, Vaginal infection, Vulval ulceration, Fatigue, Dysphonia, Fatigue, Dysphonia, Impaired healing, Urogenital fistula, Infection, Angiopathy, |
||||
PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 449 | 25046595 |
PK |
36 | 2 |
Malignant neoplasm progression, Breast cancer stage II, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, CAPECITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, LEUPROLIDE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB, ZOLEDRONIC ACID, |
||||
| 450 | 25046748 |
JP |
8 | 1 |
Acute hepatic failure, Febrile neutropenia, Malignant neoplasm progression, |
||||
NIVOLUMAB, OXALIPLATIN, PACLITAXEL, RAMUCIRUMAB, |
||||
| 451 | 25046843 |
JP |
||
Type 1 diabetes mellitus, Malignant neoplasm progression, Thyroid disorder, |
||||
PEMBROLIZUMAB, |
||||
| 452 | 25046980 |
PK |
64 | 2 |
Death, Breast cancer stage IV, Malignant neoplasm progression, |
||||
PALBOCICLIB, ANASTROZOLE, |
||||
| 453 | 25047054 |
CA |
2 | |
Disease recurrence, Synovial cyst, Breast cancer, Malignant neoplasm progression, Drug ineffective, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, |
||||
| 454 | 25047268 |
HU |
1 | |
Malignant neoplasm progression, Wrist fracture, Fall, |
||||
ENZALUTAMIDE, |
||||
| 455 | 25047270 |
AR |
2 | |
Bone cancer, Computerised tomogram abnormal, Radioisotope scan abnormal, Breast cancer metastatic, Malignant neoplasm progression, Muscle spasms, Product supply issue, Inappropriate schedule of product administration, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, ZOLEDRONIC ACID, LEUPROLIDE, |
||||
| 456 | 25047336 |
GB |
73 | 2 |
Malignant neoplasm progression, Renal impairment, Paraproteinaemia, Light chain analysis increased, |
||||
ELRANATAMAB-BCMM, |
||||
| 457 | 25047348 |
JP |
79 | 1 |
Pneumocystis jirovecii pneumonia, Pyrexia, Malignant neoplasm progression, Rash, Erythema, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 458 | 25047613 |
US |
62 | 2 |
Malignant neoplasm progression, Stomatitis, Diarrhoea, |
||||
AXITINIB, |
||||
| 459 | 25047729 |
TR |
37 | 1 |
Ophthalmic herpes simplex, Plasma cell myeloma refractory, Malignant neoplasm progression, |
||||
ELRANATAMAB-BCMM, |
||||
| 460 | 25039461 |
JP |
6 | 1 |
Pneumonia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 461 | 25040461 |
TW |
44 | |
Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, |
||||
| 462 | 25040465 |
US |
||
Malignant neoplasm progression, |
||||
IVOSIDENIB, |
||||
| 463 | 25040492 |
SI |
69 | |
Malignant neoplasm progression, Neutropenia, Bone disorder, |
||||
DURVALUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 464 | 25040585 |
DE |
||
Drug resistance mutation, Malignant neoplasm progression, |
||||
ACALABRUTINIB, |
||||
| 465 | 25040926 |
ES |
1 | |
Renal impairment, Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, |
||||
NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, SUNITINIB MALATE, SUNITINIB MALATE, SUNITINIB MALATE, |
||||
| 466 | 25041039 |
CZ |
73 | 2 |
HER2 negative breast cancer, Malignant neoplasm progression, Metastases to liver, Breast cancer metastatic, Metastases to chest wall, Pleural effusion, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, EXEMESTANE, EXEMESTANE, |
||||
| 467 | 25041200 |
JP |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 468 | 25041381 |
US |
36 | 2 |
Malignant neoplasm progression, Drug ineffective, Graft versus host disease, Posterior reversible encephalopathy syndrome, Enterobacter sepsis, Pseudomonas infection, Pneumonia fungal, Product use in unapproved indication, Product use issue, |
||||
AZACITIDINE, AZACITIDINE FOR, DECITABINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CLOFARABINE, VENETOCLAX, BUSULFAN, |
||||
| 469 | 25041547 |
US |
2 | |
Malignant neoplasm progression, Thyroid disorder, Inflammation, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 470 | 25041635 |
US |
42 | 1 |
Malignant neoplasm progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMETREXED, PEMETREXED DISODIUM, DOCETAXEL, DOCETAXEL ANHYDROUS, VINORELBINE, ENTRECTINIB, LORLATINIB, LORLATINIB, RAMUCIRUMAB, CARBOPLATIN, PEMBROLIZUMAB, PRALSETINIB, |
||||
| 471 | 25041709 |
US |
||
Haemoptysis, Malignant neoplasm progression, Product dose omission issue, |
||||
IVOSIDENIB, |
||||
| 472 | 25041991 |
US |
65 | 2 |
Malignant neoplasm progression, Nausea, |
||||
ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, FULVESTRANT, |
||||
| 473 | 25042404 |
CN |
59 | |
Metastases to meninges, Drug resistance, Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 474 | 25042556 |
CN |
62 | 2 |
Myelosuppression, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, TRASTUZUMAB, |
||||
| 475 | 25042626 |
JP |
65 | 2 |
Cellulitis, Malignant neoplasm progression, Purulence, Pyrexia, Platelet count decreased, White blood cell count decreased, Erythema, |
||||
PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, |
||||
| 476 | 25042860 |
CN |
52 | 1 |
Malignant neoplasm progression, Gastrointestinal disorder, Pyrexia, Oropharyngeal pain, Productive cough, Chest discomfort, Back pain, |
||||
AFATINIB, AFATINIB, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PACLITAXEL, PACLITAXEL, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 477 | 25042924 |
JP |
57 | 2 |
Malignant neoplasm progression, Pneumothorax, Pleural effusion, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 478 | 25043006 |
JP |
73 | 1 |
Hyponatraemia, Malignant neoplasm progression, Hypokalaemia, Neutropenia, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL, |
||||
| 479 | 25043014 |
PK |
36 | 2 |
Breast cancer stage II, Malignant neoplasm progression, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, ZOLEDRONIC ACID, RIBOCICLIB, DOCETAXEL, DOCETAXEL ANHYDROUS, TRASTUZUMAB, PERTUZUMAB, CAPECITABINE, LEUPROLIDE, |
||||
| 480 | 25043051 |
JP |
75 | 1 |
Malignant neoplasm progression, Neutropenia, Therapeutic response decreased, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CYCLOSPORINE, CYCLOSPORINE, |
||||
| 481 | 25043122 |
US |
57 | 1 |
Malignant neoplasm progression, |
||||
GEMCITABINE HYDROCHLORIDE, OLAPARIB, CISPLATIN, |
||||
| 482 | 25043222 |
US |
2 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 483 | 25043229 |
JP |
7 | 1 |
Septic pulmonary embolism, Oxygen saturation decreased, Malignant neoplasm progression, Inflammation, |
||||
IPILIMUMAB, NIVOLUMAB, NIVOLUMAB, |
||||
| 484 | 25043327 |
IL |
||
Malignant neoplasm progression, Fatigue, |
||||
CAPIVASERTIB, |
||||
| 485 | 25034182 |
JP |
8 | 1 |
Interstitial lung disease, Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 486 | 25034207 |
AU |
||
Malignant neoplasm progression, Metastases to meninges, |
||||
OSIMERTINIB, |
||||
| 487 | 25034277 |
DE |
||
Acquired gene mutation, Malignant neoplasm progression, |
||||
ACALABRUTINIB, |
||||
| 488 | 25034491 |
JP |
77 | 1 |
Pancreatic neuroendocrine tumour metastatic, Malaise, Disseminated intravascular coagulation, Metastases to liver, Malignant neoplasm progression, Oesophageal varices haemorrhage, Concomitant disease progression, Portal hypertension, Aortic aneurysm rupture, General physical health deterioration, Platelet count decreased, Lymphopenia, Blood urea increased, Blood creatinine increased, Rash, |
||||
LUTETIUM LU 177 DOTATATE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 489 | 25035058 |
SI |
||
Dermatitis, Immune-mediated myocarditis, Malignant neoplasm progression, |
||||
DURVALUMAB, METHYLPREDNISOLONE, PEMBROLIZUMAB, METHYLPREDNISOLONE, |
||||
| 490 | 25035301 |
US |
||
Malignant neoplasm progression, |
||||
ELACESTRANT, |
||||
| 491 | 25035552 |
JP |
6 | 1 |
Malignant neoplasm progression, Hepatic function abnormal, |
||||
IPILIMUMAB, NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, |
||||
| 492 | 25035660 |
CA |
2 | |
Abdominal pain, Asthenia, Blister, Blood creatine phosphokinase increased, Blood iron decreased, Blood magnesium decreased, Blood pressure decreased, Blood pressure decreased, Blood pressure diastolic decreased, Blood pressure systolic decreased, Blood pressure systolic decreased, Blood pressure systolic decreased, Blood test abnormal, Breast disorder, Constipation, Constipation, Dry mouth, Dry skin, Dry throat, Dysmenorrhoea, Eczema, Electric shock sensation, Epistaxis, Epistaxis, Faeces soft, Fatigue, Fatigue, Fatigue, Gingival pain, Headache, Headache, Headache, Heart rate decreased, Hepatitis, Hyperaesthesia, Hyperaesthesia, Hyperaesthesia, Hypotension, Hypotension, Injection site haemorrhage, Malaise, Malignant neoplasm progression, Muscular weakness, Myalgia, Nasopharyngitis, Nausea, Nausea, Pain, Palpitations, Paraesthesia, Pruritus, Recurrent cancer, Seasonal allergy, Skin fissures, Sneezing, Stress, Tumour marker increased, Urinary tract infection, Vulvovaginal pain, Weight decreased, Weight decreased, Weight increased, |
||||
HUMAN IMMUNOGLOBULIN G, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, PERTUZUMAB, PERTUZUMAB, CAPECITABINE, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, HEPARIN SODIUM AND DEXTROSE, HEPARIN SODIUM, MAGNESIUM, PACLITAXEL, METHYLPREDNISOLONE SODIUM SUCCINATE, TRAMADOL HYDROCHLORIDE, TRASTUZUMAB-QYYP, TRAMADOL HYDROCHLORIDE, |
||||
| 493 | 25036542 |
JP |
||
Malignant neoplasm progression, Fatigue, Decreased appetite, Vertigo, Sudden hearing loss, |
||||
PEMBROLIZUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 494 | 25036841 |
IL |
72 | 2 |
Cough, Renal impairment, Asthenia, Malignant neoplasm progression, Ascites, Anaemia, |
||||
ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 495 | 25036982 |
JP |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 496 | 25037187 |
JP |
60 | 1 |
Malignant neoplasm progression, Skin disorder, |
||||
PEMBROLIZUMAB, |
||||
| 497 | 25037287 |
CA |
2 | |
Malignant neoplasm progression, Metastasis, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, TAMOXIFEN CITRATE, PALBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 498 | 25037349 |
JP |
1 | |
Intestinal perforation, Peritonitis, Malignant neoplasm progression, |
||||
PIRTOBRUTINIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, CARBOPLATIN, IFOSFAMIDE, |
||||
| 499 | 25037396 |
CA |
||
Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, PALBOCICLIB, CAPECITABINE, LETROZOLE, LETROZOLE TABLETS, PACLITAXEL, OLAPARIB, |
||||
| 500 | 25037825 |
PL |
75 | 2 |
Malignant neoplasm progression, Demyelination, Neurodegenerative disorder, |
||||
PACLITAXEL, CARBOPLATIN, NIVOLUMAB, IPILIMUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28